SVS Solarvest BioEnergy Inc

SOLARVEST BIOENERGY INC. (TSX VENTURE:SVS) ("Solarvest" or the "Company") is
pleased to announce that it has granted to Dr. Angela Riveroll 70,000 options
exercisable at a price of $0.25 per common share for a period of five years from
the grant date. As Senior Research Scientist at Solarvest (PEI) Inc., Dr.
Riveroll will take a leading role in the company's genetic program to produce
hydrogen from its proprietary strains of algae.


About Solarvest: Solarvest is committed to the development of sustainable and
renewable energy sources to meet growing energy demands and environmental
challenges. Solarvest's intellectual property is a biologically-based hydrogen
producing technology, which provides a method for controlling key genes in algae
resulting in the continuous production of hydrogen gas. Solarvest's bio-energy
production system utilizes light and carbon dioxide to produce hydrogen leaving
a clean positive environmental footprint.


The statements made in this news release may contain forward-looking statements
that may involve a number of risks and uncertainties. Actual events or results
could differ materially from the Company's expectations and projections.

Grafico Azioni Solarvest BioEnergy (TSXV:SVS)
Storico
Da Ott 2024 a Nov 2024

Grafico Azioni Solarvest BioEnergy (TSXV:SVS)
Storico
Da Nov 2023 a Nov 2024